贝伐珠-话题@MedSci

#贝伐珠#

101篇内容 | 2879人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1954857, encodeId=226b195485e3a, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗联合化疗在结直肠癌中的研究概况, objectType=article, longId=221260, objectId=7e602212604d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e602212604d, replyNumber=0, likeNumber=83, createdTime=2022-11-05, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e602212604d, moduleTitle=贝伐珠单抗联合化疗在结直肠癌中的研究概况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e602212604d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954849, encodeId=639119548495a, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗在NSCLC领域的主要研究, objectType=article, longId=220754, objectId=9edd220e54ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9edd220e54ec, replyNumber=0, likeNumber=34, createdTime=2022-06-23, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9edd220e54ec, moduleTitle=贝伐珠单抗在NSCLC领域的主要研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9edd220e54ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954850, encodeId=c8a8195485023, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=贝伐珠单抗在NSCLC领域的主要研究（彭春雷）, objectType=article, longId=220756, objectId=c22e220e5698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c22e220e5698, replyNumber=0, likeNumber=31, createdTime=2022-07-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c22e220e5698, moduleTitle=贝伐珠单抗在NSCLC领域的主要研究（彭春雷）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c22e220e5698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954835, encodeId=0aab1954835e4, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, objectType=article, longId=213326, objectId=17162133260e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17162133260e, replyNumber=0, likeNumber=78, createdTime=2022-03-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17162133260e, moduleTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17162133260e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954826, encodeId=ab6c195482663, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌, objectType=article, longId=202634, objectId=735d202634e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=735d202634e5, replyNumber=0, likeNumber=52, createdTime=2021-06-10, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=735d202634e5, moduleTitle=罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=735d202634e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954831, encodeId=75d1195483168, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好, objectType=article, longId=209932, objectId=aace20993238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aace20993238, replyNumber=0, likeNumber=69, createdTime=2022-02-23, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aace20993238, moduleTitle=Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aace20993238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954834, encodeId=4b90195483457, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), objectType=article, longId=212511, objectId=4d8b21251198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8b21251198, replyNumber=0, likeNumber=71, createdTime=2022-02-06, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8b21251198, moduleTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8b21251198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954833, encodeId=0526195483368, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, objectType=article, longId=212455, objectId=f416212455b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f416212455b8, replyNumber=0, likeNumber=0, createdTime=2021-09-05, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f416212455b8, moduleTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f416212455b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954823, encodeId=4f8b1954823e4, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=东曜药业生物类似药TAB008申报上市！贝伐珠单抗国内战局白热化, objectType=article, longId=200286, objectId=f1bd20028653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bd20028653, replyNumber=0, likeNumber=59, createdTime=2021-04-12, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bd20028653, moduleTitle=东曜药业生物类似药TAB008申报上市！贝伐珠单抗国内战局白热化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bd20028653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954832, encodeId=02631954832ed, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性, objectType=article, longId=211519, objectId=7c45211519d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c45211519d9, replyNumber=0, likeNumber=108, createdTime=2021-05-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c45211519d9, moduleTitle=Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c45211519d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954829, encodeId=90b21954829a6, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案, objectType=article, longId=206078, objectId=28d22060e857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28d22060e857, replyNumber=0, likeNumber=75, createdTime=2021-08-09, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28d22060e857, moduleTitle=【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28d22060e857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954830, encodeId=f067195483017, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=“特瑞普利单抗+贝伐珠单抗”一线治疗晚期肝细胞癌临床研究新近进展发布, objectType=article, longId=208886, objectId=8dd6208886d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dd6208886d9, replyNumber=0, likeNumber=74, createdTime=2021-12-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dd6208886d9, moduleTitle=“特瑞普利单抗+贝伐珠单抗”一线治疗晚期肝细胞癌临床研究新近进展发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dd6208886d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954828, encodeId=2f9919548286a, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效, objectType=article, longId=206110, objectId=c0bd206110aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0bd206110aa, replyNumber=0, likeNumber=149, createdTime=2021-06-26, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0bd206110aa, moduleTitle=复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0bd206110aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954824, encodeId=85da19548240c, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=复宏汉霖贝伐珠单抗上市注册申请获NMPA受理, objectType=article, longId=200558, objectId=090a200558bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=090a200558bc, replyNumber=0, likeNumber=62, createdTime=2021-02-02, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=090a200558bc, moduleTitle=复宏汉霖贝伐珠单抗上市注册申请获NMPA受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=090a200558bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954825, encodeId=027f195482542, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, objectType=article, longId=201078, objectId=94a22010e8b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94a22010e8b1, replyNumber=0, likeNumber=138, createdTime=2020-11-23, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94a22010e8b1, moduleTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94a22010e8b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954819, encodeId=0a5719548190d, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗, objectType=article, longId=190232, objectId=9131190232f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9131190232f7, replyNumber=0, likeNumber=61, createdTime=2021-01-13, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9131190232f7, moduleTitle=Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9131190232f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954821, encodeId=e129195482148, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效, objectType=article, longId=192935, objectId=dc37192935a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc37192935a7, replyNumber=0, likeNumber=83, createdTime=2021-02-15, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc37192935a7, moduleTitle=Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc37192935a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954827, encodeId=07c7195482e0f, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, objectType=article, longId=203674, objectId=94d42036e4b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94d42036e4b2, replyNumber=0, likeNumber=63, createdTime=2021-05-30, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94d42036e4b2, moduleTitle=信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94d42036e4b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954822, encodeId=61551954822d7, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=信达生物贝伐珠单抗生物类似药——达攸同上市, objectType=article, longId=196189, objectId=c48d19618953, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c48d19618953, replyNumber=0, likeNumber=71, createdTime=2020-09-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c48d19618953, moduleTitle=信达生物贝伐珠单抗生物类似药——达攸同上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c48d19618953)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1954818, encodeId=dad81954818eb, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, objectTitle=Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期, objectType=article, longId=187111, objectId=646618e11101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=646618e11101, replyNumber=0, likeNumber=76, createdTime=2020-03-24, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=646618e11101, moduleTitle=Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=646618e11101)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

贝伐珠

2020-05-29

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗联合化疗在结直肠癌中的研究概况

2022-11-05

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗在NSCLC领域的主要研究

2022-06-23

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

贝伐珠单抗在NSCLC领域的主要研究（彭春雷）

2022-07-15

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性

2022-03-25

一叶知秋 (审核中...)

前往app查看评论内容

#贝伐珠#

罗氏阿替利珠单抗+贝伐珠单抗联合方案在中国获批，用于一线治疗肝细胞癌

2021-06-10

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Pediatr Blood Cancer：放疗联合VPA和贝伐珠单抗治疗胶质瘤的耐受性良好

2022-02-23

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39)

2022-02-06

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益

2021-09-05

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

东曜药业生物类似药TAB008申报上市！贝伐珠单抗国内战局白热化

2021-04-12

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Liver Cancer：网状meta分析比较atezolizumab联合贝伐珠单抗对比其他治疗手段在不可切除肝细胞癌的疗效和安全性

2021-05-25

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

【瞩目】铂敏感复发性卵巢癌：卡铂-多柔比星-贝伐珠单抗或许是新的标准治疗方案

2021-08-09

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

“特瑞普利单抗+贝伐珠单抗”一线治疗晚期肝细胞癌临床研究新近进展发布

2021-12-25

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

复发性卵巢癌：帕博利珠单抗联合贝伐珠单抗和环磷酰胺治疗安全有效

2021-06-26

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

复宏汉霖贝伐珠单抗上市注册申请获NMPA受理

2021-02-02

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择

2020-11-23

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Lancet oncol：3期试验：FOLFOXIRI+贝伐珠单抗预治疗/再治疗转移性结直肠癌的效果优于mFOLFOX6+贝伐单抗/FOLFIRI+贝伐单抗

2021-01-13

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Lancet oncol：3期试验：卡铂-聚乙醇化脂质体多柔比星-贝伐珠单抗治疗铂敏感性复发性卵巢癌的疗效

2021-02-15

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

信达生物公布信迪利单抗联合贝伐珠单抗一线治疗肝癌III期临床研究结果

2021-05-30

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

信达生物贝伐珠单抗生物类似药——达攸同上市

2020-09-25

仁医06 (审核中...)

前往app查看评论内容

#贝伐珠#

Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期

2020-03-24

科室
- - 订阅+
  - 更多科室
工具
服务